Orsini has been named the single-source specialty pharmacy partner for Glaukos' Epioxa, a novel corneal cross-linking treatment for keratoconus, a rare eye disease that thins the cornea and causes vision distortion. Epioxa, which received FDA approval in October 2025, is an oxygen-enriched topical therapy bioactivated by UV light. Unlike traditional procedures, it does not require removal of the corneal epithelium, reducing pain and streamlining recovery whilst delivering clinical outcomes. Orsini, a specialty pharmacy focused on rare diseases since 1987, has partnered with Glaukos for over five years serving the keratoconus community. The company provides integrated pharmacy solutions including distribution, patient services and home infusion for rare disease treatments.

Orsini has been selected as the exclusive specialty pharmacy and hub services partner for LOARGYS (pegzilarginase-nbln) by Immedica Pharma US Inc. LOARGYS is the first therapy approved to lower arginine in patients aged two years and older with Arginase 1 Deficiency, an ultra-rare metabolic disease affecting approximately 250 people in the US. Through this partnership, Orsini will assist patients, caregivers and healthcare providers with medication access, insurance coverage and financial assistance. The company will also provide third-party logistics services for Immedica. LOARGYS is indicated for treating hyperargininemia in adult and paediatric patients with ARG1-D, used alongside dietary protein restriction. Clinical trials showed hypersensitivity reactions occurred in 13% of treated subjects, with life-threatening reactions possible including anaphylaxis.

ELK GROVE VILLAGE, Ill., April 25, 2025 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, announced today the launch of ORBIT Track™, an innovative, next-generation portal designed to transform how Orsini connects with biopharma partners. This powerful platform delivers real-time visibility into critical patient case information and streamlined collaboration tools to enhance care for patients living with rare and complex conditions.This launch builds upon the momentum of the 2024 launch of ORBIT (Orsini Rare Business Intelligence Technology). ORBIT Track™ will further strengthen the company's data-first ecosystem, built to improve outcomes for rare disease patients and partners alike.Key features of ORBIT Track™ include:Real-Time Case Visibility: Accelerate patient access to treatment with up-to-the-minute updates on case progress and milestones.Accelerate patient access to treatment with up-to-the-minute updates on case progress and milestones. Smart Collaboration Tools: Share updates and alerts through secure HIPAA-compliant messaging to streamline collaboration between biopharma partners and Orsini.Share updates and alerts through secure HIPAA-compliant messaging to streamline collaboration between biopharma partners and Orsini. Actionable Case Insights: Access comprehensive patient progress updates, benefits information and medical documentation in one centralized location.Access comprehensive patient progress updates, benefits information and medical documentation in one centralized location. Next-Level Data Security: Protect patient information through both role-based access aligned by territory and PHI masking capabilities.Protect patient information through both role-based access aligned by territory and PHI masking capabilities